Guardant Health Inc logo

GH - Guardant Health Inc News Story

$135.39 0.8  0.6%

Last Trade - 07/05/21

Sector
Healthcare
Size
Large Cap
Market Cap £9.80bn
Enterprise Value £9.13bn
Revenue £205.2m
Position in Universe 790th / 6858

BUZZ-NeoGenomics top beneficiary of community cancer care rebound - SVB Leerink

Mon 12th April, 2021 12:47pm
** SVB Leerink says based on its conversations with key
opinion leaders (KOLs), cancer patient volumes in community
clinics are rebounding, which can bode well for diagnostics firm
NeoGenomics Inc  NEO.O 
    ** Says the KOLs were optimistic about the long-term
potential of next-generation sequencing (NGS) and liquid biopsy
testing across early detection, recurrence and late stage cancer
therapy selection
    ** NGS volumes expected to continue upward trajectory as
more therapies and data become available; liquid biopsy volumes
to benefit from faster turnaround time and increased ease of use
- SVB
    ** Highlights that the community setting is a key area of
focus for NGS and liquid biopsy, as >80% cancer care occurs in
such settings, according to NEO's estimate
    ** Believes NEO, referred to as "the "emerging Amazon of
oncology diagnostics" by a KOL, should trade at a premium to its
lab testing services and testing products peers
    ** Guardant Health Inc  GH.O  and Roche's  ROG.S  Foundation
Medicine to be among other beneficiaries of heightened NGS
utilization - brokerage
    ** YTD, NEO down 10.5%, while GH up about 22% up to its last
close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.